F. Howard

A Causal Multi-modal AI Model Stratifies Residual Risk and Identifies Candidates for Treatment Escalation in Node-Positive HR+/HER2- Early Breast Cancer

PURPOSE Prognostic biomarkers that estimate residual recurrence risk after standard adjuvant therapy to guide further treatment escalation are an unmet clinical need. This study used Ataraxis Breast CTX, a causal multi-modal AI model integrating clinical variables and histopathology, to stratify residual risk in clinic...